Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
ACTIVE_NOT_RECRUITING
Status
Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Melanoma
- Recurrent Melanoma
- Unresectable Melanoma
Interventions
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Computed Tomography
- DRUG: Dabrafenib Mesylate
- PROCEDURE: Echocardiography Test
- BIOLOGICAL: Ipilimumab
- PROCEDURE: Multigated Acquisition Scan
- BIOLOGICAL: Nivolumab
- OTHER: Quality-of-Life Assessment
- DRUG: Trametinib Dimethyl Sulfoxide
Sponsor
National Cancer Institute (NCI)